Ozempic Before Colonoscopy: Do You Need to Stop?

Taking Ozempic before colonoscopy does not mean every patient must stop the medication automatically. Neither the American Gastroenterological Association nor the 2024 multisociety guidance calls for a universal hold. Your prescribing clinician and your endoscopy team make that decision together.

Two separate questions sit behind their call. First, GLP-1 drugs slow stomach emptying, which can leave food or liquid behind during deep sedation. Second, slower gut movement can affect how well the bowel-prep drink clears your colon.

Clinics tailor instructions to your dose, timing, and symptoms. A clinician-directed liquid diet is one option, though it never replaces your bowel-prep purge.

What guidance says about Ozempic before colonoscopy

An American Gastroenterological Association clinical practice update (online November 2023, print April 2024) moved away from automatic holds. The AGA clinical guidance summary says patients without nausea, vomiting, indigestion, or bloating can usually proceed.

That summary notes standard fasting of 8 hours for solids and 2 hours for liquids. The AGA adds that "patients can also be placed on a liquid diet one day prior to their procedure" instead of stopping treatment. Active symptoms may prompt a stomach ultrasound or special airway steps.

An October 2024 multisociety guidance in Surgery for Obesity and Related Diseases (print December 2024) calls itself "guidance, and not an evidence-based guideline" for care teams. It states that "the duration to hold therapy is unknown" and supports continuation when risk is low.

Risk rises with dose increases, higher doses, weekly shots, or gut symptoms. When delayed emptying is a concern, the paper describes a "preoperative liquid diet for at least 24 h" beforehand. If clinicians pause treatment, it conditionally mentions holding a daily dose that day or a weekly dose for a week.

See our guide to semaglutide before surgery for surgical care.

Two separate concerns with a GLP-1 before colonoscopy

Slowed gastric emptying means food and liquid leave the stomach more slowly. Section 12.2 of the May 2026 Ozempic prescribing information describes this effect. Section 5.10 of Ozempic and the June 2026 Wegovy prescribing information warn about deep sedation and general anesthesia.

Both labels state that "There have been rare postmarketing reports of pulmonary aspiration" in patients who fasted. Pulmonary aspiration happens when stomach contents enter the lungs under sedation. Both labels add that "Available data are insufficient to inform recommendations" on changing fasting times or pausing doses.

The March 2026 OCULUS randomized trial in JAMA Internal Medicine studied 60 adults having upper endoscopy. Significant leftover stomach contents appeared in 3.1% who held one dose, or 1 in 32 people. Among those who continued dosing, the rate was 25.0%, or 1 in 4 (21.9% difference; P = .003).

No aspiration occurred, and none of the patients with clinically significant retained stomach contents reported upper-digestive symptoms on the procedure day. Among 25 trial patients having both upper endoscopy and colonoscopy after 24 hours of clear liquids, none had significant leftover contents. Even though "The bowel preparation was deemed adequate in all patients who underwent colonoscopy (25 patients)" there, 25 patients cannot prove universal safety.

What studies show about GLP-1 bowel prep

Colon cleanliness determines how clearly your doctor sees the colon lining, graded on the Boston Bowel Preparation Scale. Lower scores mean a harder-to-see colon. Routine advice for semaglutide constipation does not replace the colonoscopy unit's diet and bowel-prep instructions.

Two meta-analyses—studies pooling earlier research—disagreed on failed prep. A 2025 meta-analysis in the American Journal of Gastroenterology (online February 2025, print July 2025) pooled 5 studies of 10,833 patients (5,434 users, 5,399 controls).

It found roughly double the odds of inadequate prep in users (odds ratio 2.10; 95% CI 1.41 to 3.13; P = 0.0003). An odds ratio compares group odds rather than giving a failure percentage. Users also averaged 0.34 points lower on the Boston cleanliness scale (P = 0.0001).

By contrast, a February 2026 meta-analysis in Gastrointestinal Endoscopy (online August 2025) pooled 6 studies. It found no difference in inadequate-prep odds (odds ratio 1.00; 95% CI 0.73 to 1.37; P = .99). Across 3 studies, average cleanliness scores were 0.36 points lower in users (P < .001).

Because both reviews pooled observational studies, neither proves skipping a dose improves prep. As of October 17, 2026, the day this article was written, an October 3, 2026 study in BMC Gastroenterology tracked repeat colonoscopies.

Across 4,870 matched diabetes patients per group, recent GLP-1 prescriptions were linked to more repeat exams within 12 months. Rates were 11.0% versus 8.9%; the abstract reports an absolute risk difference of 2.16 percentage points (hazard ratio 1.371; P = 0.0004). Still, a repeat exam is an indirect measure, and prescription records could not show who held a dose.

Tirzepatide before colonoscopy and Mounjaro before endoscopy

The same questions apply to tirzepatide before colonoscopy and Mounjaro before endoscopy. Tirzepatide targets both GIP and GLP-1 receptors. Section 12.2 of the August 2026 Mounjaro prescribing information states that "MOUNJARO delays gastric emptying" after dosing.

Section 5.9 of Mounjaro and the August 2026 Zepbound prescribing information carry the same rare aspiration warning. Procedure teams ask about every GLP-1 drug, whether branded or compounded. Share your medication name, dose, last injection date, recent dose increases, diabetes drugs, and past prep trouble.

As the FDA guide to human drug compounding explains, compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness, or quality before marketing. Semaglutide or tirzepatide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy. Each is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

Although compounded preparations are not FDA-approved, a licensed provider may still prescribe — that decision is between you and your doctor.

Missed-dose rules and when doctors stop Wegovy before colonoscopy

If your team asks you to stop Wegovy before colonoscopy or pause another shot, restarting depends on the gap length. Brand labels state rules for an unplanned missed dose, not post-colonoscopy recovery.

As covered in our Wegovy prescribing information guide, Section 2.4 requires restarting escalation at a lower dosage after two or more consecutive missed injections. Other labels lack a multiweek ladder, and none set a same-day colonoscopy restart. Your prescriber sets the restart plan for any prescription.

Symptoms to report before and during bowel prep

Call your endoscopy clinic before starting prep if you have nausea, vomiting, indigestion, bloating, or trouble keeping liquids down. Wegovy Section 5.6 notes it is "not recommended in patients with severe gastroparesis" (severely slowed stomach emptying). Teams may use stomach ultrasound, airway precautions, or rescheduling when symptoms exist.

All four labels warn about acute kidney injury associated with dehydration from vomiting or diarrhea, a concern during bowel prep. Persistent or severe abdominal pain can signal pancreatitis, whether or not it spreads to the back or comes with nausea or vomiting. If pancreatitis is suspected, the labels call for stopping the medication and seeking medical care right away.

For patients with type 2 diabetes, clinicians also weigh high blood sugar risk during any medication hold. At Promise, a licensed provider reviews every request, and not everyone qualifies.